Max Wenheng Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Max Wenheng Xie has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Amanda Slaunwhite
BC Centre for Disease Control, Vancouver, Canada
1 shared publication- Amanda Slaunwhite
BC Centre for Disease Control, Vancouver, Canada
1 shared publication Caren Rose
BC Centre for Disease Control, Vancouver, Canada
1 shared publication- Caren Rose
British Columbia Centre for Disease Control Vancouver BC Canada
1 shared publication - Mustafa Toma
Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada; St. Paul's Hospital, Providence Health Care, Vancouver, British Columbia, Canada
1 shared publication - Robert Daniel Levy
British Columbia Transplant Vancouver BC Canada
1 shared publication
Latest Publications
- Open Access
- 1 January 2023
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 10
Observational Study Examining Kidney Transplantation Outcomes Following Donation From Individuals That Died of Drug Toxicity in British Columbia, Canada
Background: The illicit drug toxicity (overdose) crisis has worsened across Canada, between 2016 and 2021 more than 28 000 individuals have died of drug toxicity. Organ donation from persons who experience drug toxicity death has increased in recent years. Objective: This study examines whether graft loss after kidney transplantation differed by donor cause of death. Design: Retrospective cohort. Setting: Provincial transplant program of British Columbia, Canada. Patients: Transplant recipients who received kidney transplantation from deceased donors aged 12 to 70 years between 2013 and 2019 (N = 1012). Measurements: Transplant recipient all cause graft loss (graft loss due to any cause including death) was compared by donor cause of death from drug toxicity or other. Methods: Five-year Kaplan-Meier estimates of all-cause graft survival, and 3-year complete as well as stratified inverse probability of treatment weighted Cox proportional hazards models were conducted. Results: Drug toxicity death donors donated to 25% (252/1012) of kidney transplantations. Drug toxicity death donors were more likely to be young, white, males, with fewer comorbidities such as diabetes or hypertension but were more likely to have a terminal serum creatinine ≥1.5 mg/dL or be hepatitis C virus (HCV) positive. Unadjusted 5-year estimate of all-cause graft survival was 97% for recipients of drug toxicity donor kidneys and 83% for recipients of non-drug toxicity donor kidneys ( P < .001). Recipients of drug toxicity death donor kidneys had decreased risk of all cause graft loss compared to recipients of non-drug toxicity death donor kidneys (hazard ratio [HR]: 0.30, 95% confidence interval [CI]: 0.12-0.77, P = .012). This is primarily due to the reduced risk of all-cause graft loss for recipients of younger (≤35 years) drug toxicity death donor kidneys (HR: 0.05, 95% CI: 0.00-0.55, P = .015). Limitations: Potential selection bias, potential unmeasured confounding. Conclusions: Donation after drug toxicity death is safe and should be considered more broadly to increase deceased donor kidney donation.
- 1 January 2023
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 10
Open AccessObservational Study Examining Kidney Transplantation Outcomes Following Donation From Individuals That Died of Drug Toxicity in British Columbia, Canada
Background: The illicit drug toxicity (overdose) crisis has worsened across Canada, between 2016 and 2021 more than 28 000 individuals have died of drug toxicity. Organ donation from persons who experience drug toxicity death has increased in recent years. Objective: This study examines whether graft loss after kidney transplantation differed by donor cause of death. Design: Retrospective cohort. Setting: Provincial transplant program of British Columbia, Canada. Patients: Transplant recipients who received kidney transplantation from deceased donors aged 12 to 70 years between 2013 and 2019 (N = 1012). Measurements: Transplant recipient all cause graft loss (graft loss due to any cause including death) was compared by donor cause of death from drug toxicity or other. Methods: Five-year Kaplan-Meier estimates of all-cause graft survival, and 3-year complete as well as stratified inverse probability of treatment weighted Cox proportional hazards models were conducted. Results: Drug toxicity death donors donated to 25% (252/1012) of kidney transplantations. Drug toxicity death donors were more likely to be young, white, males, with fewer comorbidities such as diabetes or hypertension but were more likely to have a terminal serum creatinine ≥1.5 mg/dL or be hepatitis C virus (HCV) positive. Unadjusted 5-year estimate of all-cause graft survival was 97% for recipients of drug toxicity donor kidneys and 83% for recipients of non-drug toxicity donor kidneys ( P < .001). Recipients of drug toxicity death donor kidneys had decreased risk of all cause graft loss compared to recipients of non-drug toxicity death donor kidneys (hazard ratio [HR]: 0.30, 95% confidence interval [CI]: 0.12-0.77, P = .012). This is primarily due to the reduced risk of all-cause graft loss for recipients of younger (≤35 years) drug toxicity death donor kidneys (HR: 0.05, 95% CI: 0.00-0.55, P = .015). Limitations: Potential selection bias, potential unmeasured confounding. Conclusions: Donation after drug toxicity death is safe and should be considered more broadly to increase deceased donor kidney donation.
- 28 December 2022
- Published by Wiley in Clinical Transplantation
- Vol. 37 (3) , e14866
Outcomes following heart or bilateral‐lung transplantation from donors who died of drug toxicity in British Columbia, Canada
Introduction: The illicit drug toxicity (overdose) crisis has worsened across Canada; between 2016 and 2021, more than 28,000 individuals have died of drug toxicity. Organ donation from persons who experience drug toxicity death (DTD) has increased in recent years. This study examines whether survival after heart or bilateral‐lung transplantation differed by donor cause of death.Methods: We studied transplant recipients in British Columbia who received heart (N = 110) or bilateral‐lung (N = 223) transplantation from deceased donors aged 12–70 years between 2013 and 2019. Transplant recipient survival was compared by donor cause of death from drug toxicity or other. Five‐year Kaplan‐Meier estimates of survival and 3‐year inverse probability treatment weighted Cox proportional hazards models were conducted.Results: DTD donors made up 36% (40/110) of heart and 24% (54/223) of bilateral‐lung transplantations. DTD donors were more likely to be young, white, and male. Unadjusted 5‐year recipient survival was similar by donor cause of death (heart: 87% for DTD and 86% for non‐DTD, p = .75; bilateral‐ lung: 80% for DTD and 76% for non‐DTD, p = .65). Adjusted risk of mortality at 3‐years post‐transplant was similar between recipients of DTD and non‐DTD donor heart (hazard ratio [HR]: .94, 95% confidence interval (CI): .22–4.07, p = .938) and bilateral‐lung (HR: 1.06, 95% CI: .41–2.70, p = .908).Conclusion: Recipient survival after heart or bilateral‐lung transplantation from DTD donors and non‐DTD donors was similar. Donation from DTD donors is safe and should be considered more broadly to increase organ donation.
- 28 December 2022
- Published by Wiley in Clinical Transplantation
- Vol. 37 (3) , e14866
Outcomes following heart or bilateral‐lung transplantation from donors who died of drug toxicity in British Columbia, Canada
Introduction: The illicit drug toxicity (overdose) crisis has worsened across Canada; between 2016 and 2021, more than 28,000 individuals have died of drug toxicity. Organ donation from persons who experience drug toxicity death (DTD) has increased in recent years. This study examines whether survival after heart or bilateral‐lung transplantation differed by donor cause of death.Methods: We studied transplant recipients in British Columbia who received heart (N = 110) or bilateral‐lung (N = 223) transplantation from deceased donors aged 12–70 years between 2013 and 2019. Transplant recipient survival was compared by donor cause of death from drug toxicity or other. Five‐year Kaplan‐Meier estimates of survival and 3‐year inverse probability treatment weighted Cox proportional hazards models were conducted.Results: DTD donors made up 36% (40/110) of heart and 24% (54/223) of bilateral‐lung transplantations. DTD donors were more likely to be young, white, and male. Unadjusted 5‐year recipient survival was similar by donor cause of death (heart: 87% for DTD and 86% for non‐DTD, p = .75; bilateral‐ lung: 80% for DTD and 76% for non‐DTD, p = .65). Adjusted risk of mortality at 3‐years post‐transplant was similar between recipients of DTD and non‐DTD donor heart (hazard ratio [HR]: .94, 95% confidence interval (CI): .22–4.07, p = .938) and bilateral‐lung (HR: 1.06, 95% CI: .41–2.70, p = .908).Conclusion: Recipient survival after heart or bilateral‐lung transplantation from DTD donors and non‐DTD donors was similar. Donation from DTD donors is safe and should be considered more broadly to increase organ donation.